In further studies, pathways affected during IBD progression and post treatment recovery included genes involved in tryptophan degradation, receptors of tryptophan metabolites and NAD+ turnover (i.e., IDO, KYNU, HCAR3, CD38 and NNMT) being synchronously co-regulated [61]. Here, HCAR3 is linked to irritable bowel syndrome.